Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:SANA

Sana Biotechnology Q1 2024 Earnings Report

Sana Biotechnology logo
$3.64 +0.15 (+4.30%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$3.68 +0.04 (+1.10%)
As of 05/6/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Sana Biotechnology EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Announcement Details

Quarter
Q1 2024
Date
5/8/2024
Time
N/A
Conference Call Date
Wednesday, May 8, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Sana Biotechnology's Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Sana Biotechnology's Q1 2024 Press ReleasePress Release
(8-K)
Sana Biotechnology's Q1 2024 Quarterly reportQuarterly report
(10-Q)

Sana Biotechnology Earnings Headlines

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
May 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288244/0/en/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference.html
Sana to present in vivo CAR T data as Janux drops trial
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/sana-to-present-in-vivo-car-t-data-as-janux-drops-trial/gm-GM10547883
You’re Being LIED To About The Iran War
The mainstream explanation for the Iran airstrikes may not be the full story. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there's a deeper motive behind the bombing campaign that most coverage is ignoring. If you're making investment decisions based on what you're hearing in the news, Wiggin argues you could be working with an incomplete picture.tc pixel
 |  Banyan Hill Publishing (Ad)
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
April 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/27/3282052/0/en/sana-biotechnology-announces-oral-presentation-highlighting-preclinical-data-from-in-vivo-car-t-sg293-at-the-american-society-of-gene-cell-therapy-asgct-2026-annual-meeting.html
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
April 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/sana-biotech-sana-mayo-clinic-062208874.html
Sana Biotechnology Rebalances Board Classes With Director Shift
April 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sana-biotechnology-rebalances-board-classes-with-director-shift?utm_source=marketbeat.com&utm_medium=referral
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials.

Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic.

Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.

View Sana Biotechnology Profile
Earnings Tools